Mersana Therapeutics (MRSN) Reports In-Line Q1 EPS

Mersana Therapeutics (NASDAQ: MRSN) reported Q1 EPS of ($0.19), in-line with the analyst estimate of ($0.19). Revenue for the quarter came in at $2.75 million versus the consensus estimate of $6.05 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
• NXP Semiconductors names Mike Lucarelli as new investor relations head
• Coinbase (COIN) call put ratio 1 call to 1 put as share price down 2.2%